Study on the Changes in the Blood Lipid Profile Levels of Patients with Metabolic Syndrome while Receiving Oriental Medicine Treatments for Various Diseases

  • Kim, Dong-Woung (Department of Internal Medicine, College of Oriental Medicine, Wonkwang University)
  • Published : 2009.04.25

Abstract

Among patients who visited each clinical department for oriental medical treatments, anthropometric measurement, blood pressure, fasting blood glucose and blood lipid profile level were measured at their first initial visit. 55 subject patients who were diagnosed as having metabolic syndrome and 150 mg/dL or more of triglyceride were selected as subjects whose fasting blood glucose, triglyceride, total cholesterol, HDL cholesterol and LDL cholesterol were measured after fasting. According to each patient's disease, the subject received treatments such as herb medicine, acupuncture, moxibustion, cupping therapy, physical therapy and rehabilitation therapy from each clinical department, and after an average of 4.10${\pm}$0.31 weeks, another test was performed yielding the following results. Serum triglyceride was 243.72${\pm}$13.05 mg/dL before the oriental medical treatment and 188.11${\pm}$12.17 mg/dL after the treatment where although it continued to show an abnormal value even after the treatment, there was statistically significant decrease compared to pre treatment(P<0.05). Serum total cholesterol was 207.50${\pm}$5.89 mg/dL before the oriental medical treatment and 192.37${\pm}$5.53 mg/dL after the treatment which was statistically insignificant compared to pre treatment(P>0.05). Serum HDL cholesterol was 51.19${\pm}$3.95 mg/dL before the oriental medical treatment and increased to 52.53${\pm}$1.49 mg/dL after the treatment although it was statistically insignificant compared to pre treatment(P>0.05). Serum LDL cholesterol was 110.66${\pm}$5.86 mg/dL before the oriental medical treatment and decreased to 106.12${\pm}$4.82 mg/dL after the treatment although it was statistically insignificant compared to pre treatment(P>0.05). In regards to the change of triglyceride for each sex, it was 221.84${\pm}$14.01 mg/dL before the treatment and 187.00${\pm}$15.47 mg/dL after the treatment for men, and it was 271.50${\pm}$22.78 mg/dL and 189.53${\pm}$19.76 mg/dL respectively for women where even though men and women showed the decrease of 34.84${\pm}$12.79 mg/dL and 81.96${\pm}$20.01 mg/dL respectively, both men and women continue to show abnormal values after the treatments. However, there was statistically significant decrease compared to pre treatment(P<0.05). In regards to the change of total cholesterol for each sex, with 198.24${\pm}$7.60 mg/dL for men before the treatment and 188.93${\pm}$7.45 mg/dL after the treatment, values for both before and after the treatment were within the normal range where the change value was 9.30${\pm}$5.86 mg/dL and statistically insignificant(P>0.05). For women, it was 219.26${\pm}$8.87 mg/dL and 196.73${\pm}$8.43 mg/dL respectively for women where with 22.53${\pm}$7.60 mg/dL, it decreased to the normal level after the treatment, and there was a statistically significant decrease compared to pre treatment(P<0.05). With such results, serum triglyceride and cholesterol levels of patients who have been diagnosed as having metabolic syndrome were observed to decrease after the oriental medical treatment. Especially, for both men and women, abnormally high triglyceride level decreased while the effect of lipid profile improvement for women was more significant compared to men.

Keywords

References

  1. Wilson, P.W.F., Kannel, W.B., Silbershartz, H., D'Agostino, R.B. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 159: 1104-1109, 1999 https://doi.org/10.1001/archinte.159.10.1104
  2. Grundy, S.M. A constellation of complications. The metabolic syndrome. Clin Cornerstone. 7: 36-45, 2005 https://doi.org/10.1016/S1098-3597(05)80066-3
  3. WHO(World Health Organization). Report of a WHO consultation of metabolic syndrome in definition, diagnosis, and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus. World Health Organization, Department of Noncommunicable Disease Surveillance. Geneva, 1999
  4. Reven, G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes, 37: 1595-1607, 1988 https://doi.org/10.2337/diabetes.37.12.1595
  5. Executive Summary of the Third report of the National Cholesterol Education program(NCEP) Expert Panel on Detection, Evaluation, and treatment of high Blood cholesterol in Adults(Adult Treatment Pannel III). JAMA 28: 2486-2497, 2001
  6. Einhorn, D., Reven, G.M., Cobin, R.H., Ford, E., Ganda, O.P., Handeksman, Y., Helliman, R., Jelinger, P.S., Kendall, D., Krauss, R.M., Neufeld, N.D., Petak, S.M., Rodbard, H.W., Seibel, J.A., Smith, D.A., Wilson, P.W. American college of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract, 9: 237-252, 2003
  7. H.S. Park, S.W. OH, J.H. Kang, Y.W. Park, J.M. Choi, Y.S. Kim, W.H. Choi, H.J. Yoo, Y.S. Kim. Prevalence and associated factors with metabolic syndrome in south korea-from the korean national health and nutrition examination survey 1998. Korean J of obesity(kor) 12(1):1-14, 2003
  8. Korea National Statistical Office. Statistical analysis, Cause of death. www.nso.go.kr.
  9. nternational Obesity Task Force. The Asia-Pacific perspective, Redefining obesity and its treatment. Western Pacific Region. 2000.
  10. Isomaa, B., Almgren, P., Tuomi, T., Forsen, B., Latho, K., Nissen, M. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24(4):683-689, 2001 https://doi.org/10.2337/diacare.24.4.683
  11. Liese, A.D., Mayer-Davis, E.J., Tyroler, H.A., Davis, C.E., Keil, U., Schmit, M.I., Brancati, F.L., Heiss, G. Familial components of the multiple metabolic syndrome: The ARIC study. Diabetologia 40: 963-970, 1997 https://doi.org/10.1007/s001250050775
  12. Hong, Y., Pedersen, N.L., Brismar, K., De Faire, U. Genetic and environmental architecture of the features of the insulin-resistance sydrome. Am J Hum Genet 60: 143-152, 1997
  13. ACE position statement. Guidelindes for glycemic control. Endocr Pract 9(suppl. 1):7-19, 2003
  14. Lakka, H.M., Laaksinen, D.E., Lakka, T.A. et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288: 2709-2716, 2002 https://doi.org/10.1001/jama.288.21.2709
  15. Alexander, C.M., Landsman, P.B., Teutsh, S.M., Haffner, S.M. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes, 52: 1210-1214, 2003 https://doi.org/10.2337/diabetes.52.5.1210
  16. Youl Lee Lym, Seung Wook Hwang, Hyun Jun Shim, Eun Hye Oh, Yoo Soo Chang, Be Long Cho. Prevalence and Risk Factors of the Metabolic Syndrome as Defined by NCEP-ATP III. J Korean Fam Med(kor), 24(2):135-143, 2003
  17. H.J. Lee, H.S. Kwon, Y.M. Park, H.N. Chun, Y.H. Choi, S.H. Ko, J.M. Lee, K.H. Yoon, B.Y. Cha, W.C. Lee, K.W. Lee, H.Y. Son, S.K. Kang, M.S. Ahn, J.M. Kang, D.S. Kim. Waist circumference as a risk factor for metabolic syndrome in Korean adult ; evaluation from 5 different criteria of metabolic syndrome(kor). J Kor Diabetes Assoc 29: 48-56, 2005
  18. H.S. Park, H.C. Shin, B.S. Kim, K.Y. Lee, W.S. Choi, J.A. Shin, Y.D. Nam, S.P. Bae, K.S. Chun. Prevalence and associated factors of metabolic syndrome among adults in primary care. Korean J of obesity(kor) 12(2):108-123, 2003
  19. H.C. Jang, S. Yim, N.H. Jo. Metabolic syndrome -Korean Ansung and Ansan Cohort(KAAC) Study. Korean J Med 67 Supp(kor) 2: s528-532, 2004
  20. Castelli, W.P. The triglyceride issue: A view from framnigham. Am Heart J, 112(2):432-437, 1986 https://doi.org/10.1016/0002-8703(86)90296-6
  21. Gordon, T., Castelli, W.P., Hjotland, M.C., Kannel, W.B., Dawber, T.R. High density lipoprotein as a protective factor against coronary heart disease. The ramnigham Study. Am J MED. 62(5):707-714, 1977 https://doi.org/10.1016/0002-9343(77)90874-9
  22. K.H. Lee, J.C. Son, B.T. Kim, B.H. Choi, J.S. Hye, C.K. Cha, J.Y. Choi, Y.J. Lee, Y.H. Ahn. Non-HDL Cholesterol as a risk factor of metabolic syndrome in Korean women. Korean J of obesity(kor). 16(3):102-110, 2007
  23. Shepherd, J., Blauw, G.J., Murphy, M.B., Bollen, E.L., Buckley, B.M., Cobbe, S.M. Pravastartin in elderly individuals at risk of vascular disease(PROSPER): a randomized controlled trial. Lancet 360: 1623-1630, 2002 https://doi.org/10.1016/S0140-6736(02)11600-X
  24. Park, H.S., Kim, H.K., Park, K.S., Kim, S.Y., Park, Y.B., Cho, B.Y., Lee, K.L., Koh, C.S., Min, H.K., Kim, Y.I., Shin, Y.S., Paik, H.Y. Community based epidemiologic study on serum lipid profiles and their interaction with other atherosclerotic cardiovascular risk factors in Yonchon country. Korean J Lipidology(kor) 3: 191-203, 1993
  25. Liu, S., Willett, W.C., Stampfer, M.J., Hu, F.B., Franz, M., Sampson, L., Hennekens, C.H., Manson, J.E. A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women. Am J Clin Nutr 71: 1455-1461, 2000 https://doi.org/10.1093/ajcn/71.6.1455
  26. Korea ministry for health, welfare and family affairs : From the korean national health and nutrition examination survey 1998. www.mw.go.kr
  27. Yan, J., Wo, X.D., Fan, C.L. et al. Effects of total flavonoids in hawthorn leaves on PPAR-$\gamma$, PPRE pathway regulatory system. Chni Pharm J(chin) 40(8):625-628, 2005
  28. Park, M.Y., Lee, K.S., Sung, M.K. Effects of dietary mulberry, Korean red ginseng, and banaba on glucose homeostasis in regulation to PPAP-$\alpha$, PPAP-$\gamma$, and LPL mRNA expression. Life Sci. 26: 3344-3354, 2005
  29. Kou, W.R. The basic and clinic research of Xuezhikang. Chni Prescrip Drug(chin) 7: 52-57, 2005
  30. Fan, C.L., Wo, X.D., Luo, Y. et al. Effect of curcumin on expression of human lymphocytes, Chin Phar J(chin) 40(13):980-983, 2005
  31. Ricketts, M.L., Moore, D.D., Banz, W.J. et al. Molecular mechanism of action of the soy isoflavones includes activation of promiscuous nuclear receptors. J Nutr Biochem, 6: 321-330, 2005 https://doi.org/10.1016/j.jnutbio.2004.11.008
  32. Cai, X.J. Observation of Huazhuo Jiangzhi Decoction in treating 80 patients with hyperlipidemia. Shaanxi J Tradit Chin Med(chin). 25(2):35-36, 2003
  33. Chen hanyang, Zhang Xiaoliang, Xiong Shangquan. Clinical Observation on the treatment of combined hyperlipidemia with Xiaotan Qingzhi Fang prescription and fluvastatin. Chin J GMCM May Vol 23(5):642-644, 2008